The Great (Oral) GLP-1 Scare Why the Stevanato narrative is flawed This is not something that should take you by surprise because Ive talked about it in the past, but Stevanatos stock has been weak lately (maybe an understatement): This has happened despite the company (imho) receiving incrementally positive news over the past few months
The genetics of obesity: from discovery to biology
Between 6 and 12 months, GLP1-RA users had an average weight change of 3 \
Provides multiple medication formats , subject to availability and provider approval
Therefore, the development of an oral delivery strategy for peptide GLP-1R agonists is expected to reduce these adverse effects and improve patient compliance and quality of life (Rosenstock et al., 2021)
The Science: How Oral GLP-1 Agents Work GLP-1 (glucagon-like peptide-1) receptor agonists mimic a natural gut hormone that regulates appetite, insulin secretion, and gastric emptying